Search clinical trials for: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg

Total 8 results

Oyster Point Pharma, Inc.

Completed

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

Healthy Subjects

United States
Oyster Point Pharma, Inc.

Completed

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Long Term Follow up Dry Eye Disease

United States
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Dry Eye Disease

Mexico
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Oyster Point Pharma, Inc.

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

Dry Eye Disease

China
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Dry Eye Disease

China
Oyster Point Pharma, Inc.

Completed

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

Neurotrophic Keratopathy

United States
Stephenson Eye Associates

Recruiting

A Randomized, Controlled, Double-masked, Investigator-initiated Trial to Evaluate Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray (TSUNAMI)

Dry Eye Disease

United States
The First Affiliated Hospital with Nanjing Medical...
Wu Jieping Medical Foundation

Completed

Study on the Level of Neuromuscular Blockade

Neuromuscular Blockade

China

3

Subscribe